Review calls most GLP-1 safety signals hypothesis-generating, not established toxicities

The wire

1. 01A narrative review in Current Obesity Reports separates reproducible GLP-1 receptor agonist harms from contested ones, listing neuropsychiatric, dermatological, retinopathy, NAION, aspiration, sarcopenia and malignancy associations as controversial.
2. 02Prescribers can use the framework to counsel patients on which risks warrant monitoring and which remain unproven, including the FDA's removal of the suicidality warning from GLP-1 labeling.
3. 03Most underlying evidence comes from pharmacovigilance databases, retrospective studies and secondary trial analyses, limited by reporting bias, residual confounding and inability to establish causality.

From the source

Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies

Current obesity reports · 2026 Oct 21 · Kounatidis DC, Vallianou NG, Kouveletsou M et al.